Press Enter to search · Esc to close
A network meta-analysis finally ranks the incretin heavyweights head-to-head, while a novel once-weekly peptide files its first big numbers. Here's what the data actually shows.
A new systematic review argues the number on your cholesterol panel misses the molecular story — and a parallel mortality analysis suggests insulin resistance and kidney function deserve a seat at the table.
GLP-1 receptor agonists keep finding new organs to help. A fresh slate of 2025 evidence maps where the signal is strongest — and where it's still preliminary.
A wave of 2025 research suggests GLP-1 agonists are doing more than shrinking waistlines — nudging lipid panels, reshaping fat tissue, and edging into cardiology and dermatology. The signal is real, but still moderate.
New survey and claims data suggest a quiet mismatch in cardiometabolic care: physicians may be undercounting how much weight and risk these drugs move, while many eligible adults never start them.
The dual GIP/GLP-1 agonist is moving past weight loss into lipid repair and intracranial pressure relief. But a small case series flags a risk off-label users haven't been warned about.